On February 5, 2026, Spruce Biosciences, Inc. announced that their enzyme replacement therapy (TA-ERT) significantly reduced heparan sulfate and improved outcomes in patients with Sanfilippo Syndrome Type B at a recent conference. The findings suggest stabilization in communication and motor skills compared to untreated patients, indicating potential for regulatory approval.